What is the recommended Indian protocol for influenza (flu) vaccination and pneumococcal vaccination in senior citizens aged 60 years and older?

Indian Protocol for Flu Shot and Pneumonia Vaccine for Senior Citizens

Influenza Vaccination

For senior citizens aged 60 years and older in India, annual influenza vaccination is strongly recommended, with preferential use of high-dose or adjuvanted vaccines when available. 1

Vaccine Selection and Timing

• Preferred vaccines for adults ≥65 years include:

  • High-dose inactivated influenza vaccine (HD-IIV3)
  • Recombinant influenza vaccine (RIV3)
  • Adjuvanted inactivated influenza vaccine (aIIV3)
  • If none of these are available, any age-appropriate standard-dose influenza vaccine should be administered 2

• Timing considerations for India: Given year-round influenza circulation in India, vaccination should be administered with the latest Northern Hemisphere (NH) or Southern Hemisphere (SH) strain whenever the patient presents, rather than waiting for a specific season 3

• Trivalent vaccines are currently favored over quadrivalent formulations due to absence of the B/Yamagata strain 3

Rationale for Enhanced Vaccines

The preferential recommendation for higher-dose or adjuvanted vaccines stems from evidence showing relative benefit in preventing influenza-associated hospitalizations in older adults, though the magnitude varies by season. These vaccines contain either increased hemagglutinin antigen (60 μg for HD-IIV3, 45 μg for RIV3 vs. 15 μg standard) or include the MF59 adjuvant 2. While direct comparative studies between these enhanced vaccines don't consistently show superiority of one over another, they collectively demonstrate better protection than standard-dose vaccines in this vulnerable population.

---

Pneumococcal Vaccination

For Indian senior citizens aged ≥65 years who are vaccine-naïve, administer either a single dose of PCV20 OR PCV15 followed by PPSV23 after a minimum 1-year interval.

Vaccination Schedule for Adults ≥65 Years

Option A: PCV20 Alone

• If no prior pneumococcal vaccination: Single dose of PCV20
• If prior PPSV23 only: PCV20 after ≥1 year interval from last PPSV23
• If prior PCV13 only: PCV20 after ≥1 year interval from PCV13
• If prior PCV13 + PPSV23: Generally complete; reassess based on individual risk 4

Option B: PCV15 + PPSV23 Sequential

• If no prior vaccination: PCV15, then PPSV23 after ≥1 year
• If prior PPSV23 only: PCV15 after ≥1 year from PPSV23
• If prior PCV13 only: PPSV23 after ≥1 year from PCV13 4

Special Considerations for High-Risk Seniors

For those aged 60-64 years with immunocompromising conditions (chronic renal failure, immunodeficiency, malignancy, HIV, transplant recipients, etc.):

• Option A: Single PCV20 dose
• Option B: PCV15 followed by PPSV23 after ≥8 weeks (shorter interval than general population)
• May require additional PPSV23 doses at 5-year intervals depending on condition 4

For those with chronic medical conditions (diabetes, heart disease, lung disease, smoking, alcoholism):

• Same schedule as general ≥65 population but initiate at age 60-64 years
• PCV20 alone OR PCV15 + PPSV23 (1-year interval) 4

Indian Context and Implementation

Critical gap: While multiple Indian medical societies (API, GSI, IMA, ICS-NCCP, RSSDI) recommend pneumococcal vaccination for older adults, implementation remains suboptimal 5, 6. The Indian Association of Preventive & Social Medicine (IAPSM) suggests:

• Initial phase: Target high-risk populations (those with comorbidities, immunosuppression)
• Preferred regimen in India: PCV13 followed by PPSV23 after 1 year (based on current vaccine availability) 5
• For those ≥65 years: PPSV23 is recommended at minimum 5

Common Pitfalls to Avoid

1. Don't administer PCV and PPSV23 simultaneously - maintain appropriate intervals (1 year for general population, 8 weeks for immunocompromised)
2. Don't repeat PCV20 if patient already received PCV13 + PPSV23 - they are generally adequately protected
3. Don't use outdated schedules - PCV13 alone is no longer sufficient; either upgrade to PCV20 or add PPSV23
4. Don't delay influenza vaccination waiting for "flu season" - in India's tropical climate, vaccinate when patient presents 3

Safety Profile

Both vaccines are well-tolerated with predominantly mild adverse events (injection site pain, swelling, low-grade fever). No significant safety concerns differentiate between vaccine options 5.

---

Practical Implementation Algorithm

For a senior citizen ≥60 years presenting for vaccination:

1. Check vaccination history
2. Assess comorbidities and immune status
3. Influenza: Administer HD-IIV3, RIV3, or aIIV3 if available; otherwise standard-dose vaccine
4. Pneumococcal:
   • If vaccine-naïve → PCV20 (if available) OR PCV15 now + schedule PPSV23 in 1 year
   • If immunocompromised → Use 8-week interval for PCV15-PPSV23 sequence
   • If prior incomplete series → Follow tables above based on what was received
5. Document and schedule follow-up for second pneumococcal dose if needed

Both vaccines can be administered during the same visit at different injection sites.